Segall Bryant & Hamill LLC Has $2.39 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Segall Bryant & Hamill LLC grew its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 51.8% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 79,518 shares of the biopharmaceutical company’s stock after purchasing an additional 27,128 shares during the period. Segall Bryant & Hamill LLC’s holdings in TG Therapeutics were worth $2,393,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Bleakley Financial Group LLC bought a new stake in TG Therapeutics during the fourth quarter worth $245,000. Castellan Group bought a new stake in shares of TG Therapeutics in the 4th quarter worth $8,539,000. Barclays PLC grew its stake in shares of TG Therapeutics by 83.9% in the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock worth $8,117,000 after acquiring an additional 158,323 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of TG Therapeutics by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock valued at $16,859,000 after purchasing an additional 270,286 shares during the last quarter. Finally, Neo Ivy Capital Management bought a new position in shares of TG Therapeutics during the third quarter valued at about $2,358,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Stock Down 1.4 %

TGTX opened at $40.20 on Friday. TG Therapeutics, Inc. has a twelve month low of $12.93 and a twelve month high of $43.32. The company’s 50-day moving average price is $34.17 and its two-hundred day moving average price is $30.18. The stock has a market cap of $6.31 billion, a price-to-earnings ratio of -401.96 and a beta of 2.30. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. As a group, equities analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TGTX has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.67.

Insider Activity

In related news, CFO Sean A. Power sold 11,337 shares of the business’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the sale, the chief financial officer now directly owns 670,632 shares in the company, valued at approximately $20,313,443.28. The trade was a 1.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 10.50% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.